NAGLAZYME (Galsulfage) Logo

Cost concerns, billing, and reimbursement

BioMarin is committed to working with all individuals, healthcare providers, and payors involved in patients’ care to help make NAGLAZYME^® (galsulfase) treatment as easy and seamless as possible.

The BioMarin Patient and Physician Support program is a free, confidential service staffed by patient advocates who will help coordinate health insurance and treatment plans so you and your clinic staff don’t have to.

Learn how BPPS can assist with:

Securing/maintaining insurance coverage
Identifying treatment centers
Setting up infusion appointments
Answering reimbursement questions

BPPS bridges the insurance gap

Patient Assistance Programs are available to certain qualified patients who may need financial assistance to begin or continue NAGLAZYME therapy.

Early diagnosis and treatment may help patients go farther. Contact BBPS toll-free at 1-866-906-6100, option 1.

Next: General patient care – palliative Rx

Long-term Compliance

Looking for invaluable MPS VI practice resources? Visit the Clinical Resources section.

IMPORTANT SAFETY INFORMATION

NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI). NAGLAZYME has been shown to improve walking and stair-climbing capacity.

The most common adverse events observed in clinical trials in patients treated with NAGLAZYME were headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and otitis media. Severe reactions included agioneurotic edema, hypotension, dyspnea, bronchospasm, respiratory distress, apnea, and urticaria. The most common symptoms of infusion reactions included fever, chills/rigors, headache, rash, and mild to moderate urticaria. Nausea, vomiting, elevated blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain were also reported. No patients discontinued infusions of NAGLAZYME for adverse events and all patients who completed the double-blind portion of the trial continued to receive weekly infusions of NAGLAZYME. Nearly all patients developed antibodies as a result of treatment, but the level of the immune response did not correlate with the severity of adverse events. Because antihistamine use may increase the risk of apneic episodes, evaluation of airway patency should be considered prior to the initiation of treatment. Consideration to delay infusion of NAGLAZYME should be given when treating patients who present with acute febrile or respiratory illness.

Please see full prescribing information (PDF 440KB)

Region:

Text Size

NAGLAZYME (Galsulfage) Logo

Managing MPS VI with NAGLAZYME

Cost concerns, billing, and reimbursement

BPPS bridges the insurance gap

Long-term Compliance

Long-term Compliance

IMPORTANT SAFETY INFORMATION